Healthcare Industry News: sinusitis
News Release - November 7, 2006
Naryx Pharma, Inc. Announces the Election of Geron Corporation Executive Alan B. Colowick to its Board of DirectorsSANTA BARBARA, Calif.--(HSMN NewsFeed)--Naryx Pharma, Inc., a leader in the development of new therapies for patients with chronic sinusitis, announced today that Alan B. Colowick, M.D., M.P.H., has been elected to its Board of Directors.
Dr. Colowick was recently appointed President, Oncology of Geron Corporation, where he manages the operational and strategic activities of the company's oncology programs. Prior to joining Geron, Dr. Colowick was the chief medical officer of Threshold Pharmaceuticals, Inc., where he was responsible for all aspects of non-clinical and clinical development and manufacturing. He also held a number of positions with Amgen Inc., including Vice President of European Medical Affairs and Director of Clinical Affairs, where he led the team responsible for the company's successful multinational approvals and launches of Aranesp®. Dr. Colowick was a clinical and research fellow in hematology and oncology at Harvard University and Dana Farber Cancer Institute. He earned his M.P.H. at the Harvard School of Public Health and his M.D. at Stanford University School of Medicine. "Naryx is distinguishing itself as a leader in targeted delivery of important therapies for chronic sinusitis," said Dr. Colowick. "I look forward to joining the Board of Directors and helping the company develop and commercialize these therapies in an area of significant unmet medical need."
"We are thrilled that Alan has agreed to join our board," said Michael Narachi, Chairman of the Board. "Alan has a broad background in all aspects of product development, registration, and commercialization, and we know that this experience will be a key resource as we continue to develop new therapies for chronic sinusitis."
About Naryx Pharma
Naryx(TM) is a privately-held company dedicated to developing innovative therapies for chronic sinusitis, based on advances in the targeted delivery of medications. Chronic sinusitis is a disease that afflicts up to 30 million people in the U.S. alone. The Company will focus on obtaining marketing approvals for its promising intellectual property portfolio of intranasal drug formulations.
Source: Naryx Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.